MedTrace Logo

Commerical DHA Supplementation

NCT05415293 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-01-11

No results posted yet for this study

Summary

The purpose of this study is to compare blood levels of women who take commericially available, low dose docosahexaenoic acid (DHA) dietary supplements in pregnancy with women who do not take supplements.

Conditions

  • Randomized Clinical Trial
  • Docosahexaenoic Acid
  • Pregnancy

Interventions

DIETARY_SUPPLEMENT

Expecta 200mg DHA

DIETARY_SUPPLEMENT

Promise 275mg DHA

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • University of New Mexico

    lead OTHER

Principal Investigators

  • Steffen A Brown, MD · University of New Mexico

  • Ellen L Mozurkewich, MD, MS · University of New Mexico

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05415293 on ClinicalTrials.gov